Flagship launches genetic medicine start-up Mirai Bio

The venture capital firm Flagship Pioneering has unveiled its latest spin-off: Mirai Bio, which aims to optimize genetic medicines—both the vehicles that carry them and their genetic cargo, such as RNA. Mirai will function without an internal pipeline of drugs—similar to a contract development and manufacturing organization. Endpoints News reports that the start-up is designing lipid nanoparticles with the goal of delivering medicines to the eye, immune and fat cells, bone marrow, central nervous system, and skeletal muscle.